HEART failure patients have another therapy option, with today's announcement that the Therapeutic Goods Administration (TGA) has approved Kerendia (finerenone, Bayer) for the treatment of adults with symptomatic heart failure and left ventricular ejection fraction (LVEF) 40%.
The oral, once-daily, non-steroidal mineralocorticoid receptor antagonist (MRA) is also approved for cardiovascular and renal risk reduction in patients with chronic kidney disease associated with type 2 diabetes.
"By targeting the inflammation and fibrosis that contribute to disease progression, this nonsteroidal MRA works differently to existing therapies and helps reduce worsening heart failure events when added to usual care," said Bayer's head of medical affairs in APAC, Dr Eduardo Pimenta.
Bayer is working to get Kerendia listed on the PBS.
The above article was sent to subscribers in Pharmacy Daily's issue from 09 Mar 26
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 09 Mar 26
